MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) said it is entering 2026 with optimism, citing accelerating demand for its mustard-derived biofertility product TerraSante in the US, ongoing biopesticide registration efforts for TerraMG, and a rebound anticipated in its Canadian sales and distribution division, NexusBioAg.
In a letter to shareholders, CEO Corey Giasson highlighted a “transformational” 2025 as the company transitioned from product development to commercialization.
“For TerraSante, the response from large US commercial farming operations has exceeded our expectations as exhibited through strong repeat demand,” Giasson wrote. “For our Canadian distribution business, NexusBioAg, we are anticipating a typical cyclical rebound for farmers and our business in 2026.”
The company said field trials of TerraSante have demonstrated yield and crop quality improvements, with one Washington state farmer reporting a two-ton per acre increase in potatoes and approximately a 35% rise in top-grade produce, translating to a roughly US$5,000 per acre gain in value against an estimated US$180 per acre product cost.
Giasson said MustGrow has begun scaling up manufacturing in 2026 to meet growing US demand, with contract manufacturers in Asia preparing dedicated continuous production lines. The company is also exploring additional production partners to support expansion.
Interest from international sales and distribution groups has also been noted, with potential registrations and sales of TerraSante in other countries under consideration.
On the biopesticide front, MustGrow is advancing TerraMG registrations in Canada and the US, leveraging two years of field trial data, particularly for clubroot disease in canola. The company’s partnership with Bayer AG in Europe, the Middle East, and Africa is progressing, with Bayer allocating resources toward TerraMG registration and the next milestone payment expected soon.
MustGrow’s Canadian distribution division, NexusBioAg, is expected to benefit from a cyclical rebound in 2026 after a challenging 2025 marked by droughts, tariffs, and higher input costs. Giasson described NexusBioAg as a “ready-made sales channel” for the company’s proprietary products.
MustGrow’s forward-looking strategy emphasizes scaling production, expanding market reach for its biofertility and biopesticide products, and leveraging its integrated sales and distribution platform to drive growth in 2026.
Shares of MustGrow added 5.3% on Thursday at $0.60 in Canada.